The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...